President Donald Trump has signed an executive order introducing significant pharmaceutical tariffs. Companies failing to strike pricing deals with the administration face up to 100 per cent tariffs on patented drugs. Those building US facilities may see reduced or zero tariffs. This move aims to reshape drug pricing and boost domestic manufacturing.